Feasibility Study of the AffloVest in Bronchiectasis

Inclusion Criteria: * Adult male and females 18 years or over * Current diagnosis of bronchiectasis * Productive of sputum on a daily basis * Clinical stability over a 2 week period prior to enrolment Exclusion Criteria: * Cystic fibrosis * Severe obstructive airways disease (defined as FEV1 less than 25 percent) * Predominant lung disease is not bronchiectasis in the opinion of the investigator (e.g. asthma, Chronic Obstructive Pulmonary Disease (COPD), pulmonary fibrosis) * Bronchiectasis in only 1 lobe * Currently treated non-tuberculous mycobacterial lung disease * Acute congestive cardiac failure * Contra-indication or unable to perform HRCT imaging, including pregnancy * Contra-indication to using AffloVest including lung malignancy, recent rib fractures, radiological evidence of lung cavitation, and recent significant haemoptysis (in the opinion of the investigator) * History of poor adherence to physiotherapy treatment * Cognitive or memory problems affecting ability to follow instructions or give informed consent